Raymond James Initiates Coverage On Camp4 Therapeutics with Strong Buy Rating, Announces Price Target of $10
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsInitiationPrice Target
Raymond James analyst Tiago Fauth initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Strong Buy rating and announces Price Target of $10.
Raymond James analyst Tiago Fauth initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Strong Buy rating and announces Price Target of $10.